Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation

Minoru Tanabe, Motohide Shimazu, Go Wakabayashi, Ken Hoshino, Shigeyuki Kawachi, Tomohisa Kadomura, Hiroaki Seki, Yasuhide Morikawa, Masaki Kitajima

研究成果: Article

123 引用 (Scopus)

抄録

Background. ABO-incompatible liver transplantation is associated with an extremely complicated postoperative course, especially when the recipients are adults. Methods. Two adult patients underwent living-donor liver transplantation from ABO-incompatible donors. The antirejection therapy included multiple perioperative plasmapheresis, splenectomy, systemic triple immunosuppressive regimen with tacrolimus, methylprednisolone, and cyclophophamide, or azathioprine. In addition to these conventional approaches, we performed intraportal infusion therapy after transplantation with methylprednisolone, prostaglandin E1, and gabexate mesilate. Results. With our protocol, antidonor blood group antibody titers in both cases remained low without any evidence of rejection or vascular complications throughout the postoperative course. Biliary complications were transient and resolved completely. The patients have now survived 30 and 12 months posttransplantation and have regained normal life activity with good liver function. Conclusions. Our experience has shown the feasibility of controlling rejection and other complications in adult ABO-incompatible liver transplantation under intraportal infusion therapy.

元の言語English
ページ(範囲)1959-1961
ページ数3
ジャーナルTransplantation
73
発行部数12
出版物ステータスPublished - 2002 6 27

Fingerprint

Liver Transplantation
Methylprednisolone
Gabexate
Plasmapheresis
Alprostadil
Living Donors
Azathioprine
Tacrolimus
Splenectomy
Immunosuppressive Agents
Blood Group Antigens
Immunosuppression
Blood Vessels
Therapeutics
Transplantation
Tissue Donors
Antibodies
Liver

ASJC Scopus subject areas

  • Transplantation
  • Immunology

これを引用

Tanabe, M., Shimazu, M., Wakabayashi, G., Hoshino, K., Kawachi, S., Kadomura, T., ... Kitajima, M. (2002). Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation, 73(12), 1959-1961.

Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. / Tanabe, Minoru; Shimazu, Motohide; Wakabayashi, Go; Hoshino, Ken; Kawachi, Shigeyuki; Kadomura, Tomohisa; Seki, Hiroaki; Morikawa, Yasuhide; Kitajima, Masaki.

:: Transplantation, 巻 73, 番号 12, 27.06.2002, p. 1959-1961.

研究成果: Article

Tanabe, M, Shimazu, M, Wakabayashi, G, Hoshino, K, Kawachi, S, Kadomura, T, Seki, H, Morikawa, Y & Kitajima, M 2002, 'Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation', Transplantation, 巻. 73, 番号 12, pp. 1959-1961.
Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S, Kadomura T その他. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation. 2002 6 27;73(12):1959-1961.
Tanabe, Minoru ; Shimazu, Motohide ; Wakabayashi, Go ; Hoshino, Ken ; Kawachi, Shigeyuki ; Kadomura, Tomohisa ; Seki, Hiroaki ; Morikawa, Yasuhide ; Kitajima, Masaki. / Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. :: Transplantation. 2002 ; 巻 73, 番号 12. pp. 1959-1961.
@article{79fff2d8dfc5483394dddcc412190194,
title = "Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation",
abstract = "Background. ABO-incompatible liver transplantation is associated with an extremely complicated postoperative course, especially when the recipients are adults. Methods. Two adult patients underwent living-donor liver transplantation from ABO-incompatible donors. The antirejection therapy included multiple perioperative plasmapheresis, splenectomy, systemic triple immunosuppressive regimen with tacrolimus, methylprednisolone, and cyclophophamide, or azathioprine. In addition to these conventional approaches, we performed intraportal infusion therapy after transplantation with methylprednisolone, prostaglandin E1, and gabexate mesilate. Results. With our protocol, antidonor blood group antibody titers in both cases remained low without any evidence of rejection or vascular complications throughout the postoperative course. Biliary complications were transient and resolved completely. The patients have now survived 30 and 12 months posttransplantation and have regained normal life activity with good liver function. Conclusions. Our experience has shown the feasibility of controlling rejection and other complications in adult ABO-incompatible liver transplantation under intraportal infusion therapy.",
author = "Minoru Tanabe and Motohide Shimazu and Go Wakabayashi and Ken Hoshino and Shigeyuki Kawachi and Tomohisa Kadomura and Hiroaki Seki and Yasuhide Morikawa and Masaki Kitajima",
year = "2002",
month = "6",
day = "27",
language = "English",
volume = "73",
pages = "1959--1961",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation

AU - Tanabe, Minoru

AU - Shimazu, Motohide

AU - Wakabayashi, Go

AU - Hoshino, Ken

AU - Kawachi, Shigeyuki

AU - Kadomura, Tomohisa

AU - Seki, Hiroaki

AU - Morikawa, Yasuhide

AU - Kitajima, Masaki

PY - 2002/6/27

Y1 - 2002/6/27

N2 - Background. ABO-incompatible liver transplantation is associated with an extremely complicated postoperative course, especially when the recipients are adults. Methods. Two adult patients underwent living-donor liver transplantation from ABO-incompatible donors. The antirejection therapy included multiple perioperative plasmapheresis, splenectomy, systemic triple immunosuppressive regimen with tacrolimus, methylprednisolone, and cyclophophamide, or azathioprine. In addition to these conventional approaches, we performed intraportal infusion therapy after transplantation with methylprednisolone, prostaglandin E1, and gabexate mesilate. Results. With our protocol, antidonor blood group antibody titers in both cases remained low without any evidence of rejection or vascular complications throughout the postoperative course. Biliary complications were transient and resolved completely. The patients have now survived 30 and 12 months posttransplantation and have regained normal life activity with good liver function. Conclusions. Our experience has shown the feasibility of controlling rejection and other complications in adult ABO-incompatible liver transplantation under intraportal infusion therapy.

AB - Background. ABO-incompatible liver transplantation is associated with an extremely complicated postoperative course, especially when the recipients are adults. Methods. Two adult patients underwent living-donor liver transplantation from ABO-incompatible donors. The antirejection therapy included multiple perioperative plasmapheresis, splenectomy, systemic triple immunosuppressive regimen with tacrolimus, methylprednisolone, and cyclophophamide, or azathioprine. In addition to these conventional approaches, we performed intraportal infusion therapy after transplantation with methylprednisolone, prostaglandin E1, and gabexate mesilate. Results. With our protocol, antidonor blood group antibody titers in both cases remained low without any evidence of rejection or vascular complications throughout the postoperative course. Biliary complications were transient and resolved completely. The patients have now survived 30 and 12 months posttransplantation and have regained normal life activity with good liver function. Conclusions. Our experience has shown the feasibility of controlling rejection and other complications in adult ABO-incompatible liver transplantation under intraportal infusion therapy.

UR - http://www.scopus.com/inward/record.url?scp=0037182836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037182836&partnerID=8YFLogxK

M3 - Article

C2 - 12131697

AN - SCOPUS:0037182836

VL - 73

SP - 1959

EP - 1961

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -